Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children

Downloaded from https://aidsinfo.nih.gov/guidelines on 8/18/2019

Visit the AIDSTinfo website to access the most up-to-date guideline.

Register for e-mail notification of guideline updates at https://aidsinfo.nih.gov/e-news.
Human Herpesvirus 8 Disease  (Last updated December 15, 2016; last reviewed December 15, 2016)

Panel’s Recommendations

I. Is there an indication for serologic testing for human herpesvirus 8 (HHV-8) in asymptomatic HIV-infected children (compared with not testing) to guide clinical management?
Antibody (or DNA testing) for HHV-8 is insufficiently sensitive/specific to predict risk of Kaposi sarcoma. Therefore, routine testing to identify HHV-8-seropositive, HIV-infected patients is not recommended (strong, very low).

II. Among HIV-infected children, does initiation of antiretroviral therapy (ART) (as compared with non-initiation) reduce the risk of Kaposi sarcoma?
Effective suppression of HIV replication with ART is recommended to reduce the risk of HHV-8-associated Kaposi sarcoma (strong, low).

III. For HIV-infected patients initiating ART, are any specific ART regimens associated with lower rates of Kaposi sarcoma?
Data are insufficient and conflicting upon which to base a recommendation for a particular ART regimen for prevention of Kaposi sarcoma (weak, low).

IV. Among HIV-infected children with active Kaposi sarcoma, is treatment with ART (as compared with no ART) associated with higher rates of remission and/or decreased mortality?
Treatment with ART is associated with increased survival among HIV-infected children with active Kaposi sarcoma. Effective suppression of HIV replication with ART is recommended for all patients with evidence of active Kaposi sarcoma and other HHV-8-associated malignant lymphoproliferative disorders (strong, very low).

V. Among HIV-infected children with active Kaposi sarcoma, is treatment with chemotherapy in addition to ART (as compared with ART alone) associated with higher rates of remission and/or decreased mortality?
Systemic chemotherapy, in addition to ART, is associated with higher rates of remission and decreased mortality and is recommended for disseminated or visceral Kaposi sarcoma (stage T1 disease) and for primary effusion lymphoma (strong, low). For localized Kaposi sarcoma (stage T0 disease), the benefit of systemic chemotherapy (in addition to ART) is unclear.

VI. Among HIV-infected children treated with ART who develop immune reconstitution inflammatory syndrome (IRIS), is chemotherapy in addition to continuation of ART (compared with no chemotherapy) associated with higher rates of remission and/or decreased mortality?
For patients with Kaposi-sarcoma-associated IRIS, chemotherapy along with continuation of ART is recommended (strong, low).

VII. Among HIV-infected children who achieve remission from Kaposi sarcoma, what therapies are recommended to lower the risk of recurrence?
Effective suppression of HIV replication with ART in HIV-infected patients with Kaposi sarcoma may prevent Kaposi sarcoma progression or occurrence of new lesions and may decrease risk of recurrence after remission. Life-long ART is recommended for all individuals with evidence of active or treated Kaposi sarcoma or other HHV-8-associated malignant lymphoproliferative disorders (strong, low).

Rating System

Strength of Recommendation: Strong; Weak
Quality of Evidence: High; Moderate; Low; or Very Low

Introduction/Overview

Epidemiology

Human herpesvirus 8 (HHV-8), also called Kaposi sarcoma (KS)-associated herpesvirus (KSHV), is a gamma human herpesvirus most closely related to Epstein-Barr virus. HHV-8 has been causally linked to all forms of KS (i.e., HIV-related, classic endemic, and iatrogenic) and with two rare neoplastic conditions usually associated with HIV infection: body cavity-based lymphoma, also known as primary effusion lymphoma (a B-cell lymphoma that typically arises in body cavities such as the pleural space), and multicentric Castleman disease (non-cancerous tumors that may develop in lymph nodes in a single site or in multiple sites throughout the body). The exact mechanism by which HHV-8 infection leads to neoplastic disease has not been fully elucidated, but seroconversion to HHV-8 antibody positivity virtually always
The prevalence of antibodies to HHV-8 varies widely with age, geography, and certain risk factors. In the United States and Europe, 1% to 3% of the general adult population is seropositive, with higher rates (8%) among men who have sex with men (MSM). In a U.S. cohort of HIV-infected and at-risk (but HIV-negative) adolescents with a median age of 19 years, 11.2% were HHV-8 seropositive. The highest rates were in adolescent HIV-infected MSM (23%). Seropositivity was associated with HIV infection, MSM, a history of syphilis, and injection-drug use. The general adult seropositivity rate in Mediterranean countries ranges from 10% to 25%. In areas where HHV-8 is endemic, such as eastern and central sub-Saharan Africa, HHV-8 seropositivity rates as high as 80% have been reported in adults.

HHV-8 is transmitted through oral and, possibly, genital secretions. Immunocompetent HHV-8-infected adults frequently shed HHV-8 in their oropharyngeal secretions. In areas where HHV-8 infection is endemic, the seroprevalence increases quickly during the first 5 years of life (especially when other family members are HHV-8-positive), then plateaus until adolescence and young adult years. The seroprevalence among infants and children increases with the number of HHV-8-positive parents and siblings in the home, indicating non-sexual transmission for prepubertal children, with a limited role for perinatal transmission. HHV-8 can also be transmitted through exposure to infected blood, including through intravenous (IV) drug use and blood product transfusions.

For HIV-infected individuals, coinfection with HHV-8 places them at increased risk of KS. Most cases of KS occur in adults (compared with children). Before the advent of antiretroviral therapy (ART), the overall incidence of KS in HIV-infected adults was as high as 20%. However, in the United States and England, KS represented less than 1% of pediatric AIDS-defining illnesses, likely due in part to low HHV-8 seroprevalence in children in these regions. Although KS occurs primarily in adults, the incidence in children has increased dramatically as a result of the HIV pandemic, particularly in sub-Saharan Africa. Iatrogenic KS has emerged as well, predominantly among adults in developed settings, with increasing use of immunosuppressive therapies and organ transplantation. Pediatric cases of iatrogenic KS after liver or bone marrow transplantation have also been described.

The incidence of KS among HIV-infected individuals is highest among those with severe immunodeficiency. KS, primary effusion lymphoma, and multicentric Castleman disease can occur at any CD4 T lymphocyte (CD4) cell count, but they are described most often in HIV-infected patients with more advanced immunosuppression (CD4 cell count <200 cells/mm³ in adults). It should be noted, however, that 5% to 10% of newly diagnosed KS in adults occurs in those with CD4 cell count >300/mm³ and/or low or undetectable plasma HIV RNA levels.

The incidence of KS appeared to decline in the United States even before the widespread use of ART. The reason is unclear but may have been related to the use of other antiviral agents, such as those used to treat cytomegalovirus (CMV) (i.e., foscarnet, ganciclovir, and cidofovir), which may inhibit HHV-8. The incidence of KS in adults has continued to decrease with the advent of earlier and more aggressive ART.

**Clinical Manifestations**

Primary infection with HHV-8 in young, immunocompetent children may be asymptomatic or may present as a self-limited mononucleosis-like illness consisting of fever, mild upper respiratory symptoms, and a maculopapular rash. A similar presentation has been described in immunocompetent adults. A more severe illness has been described in immunocompromised patients, who may present with disseminated infection with fever, lymphadenopathy, splenomegaly, and pancytopenia. Reactivation of HHV-8 has been associated with hemophagocytic lymphohistiocytosis in HIV-infected adults.

KS presentation varies widely, with cutaneous, oral, lymphatic, or visceral involvement, or some combination of the three. Pediatric presentations differ from those of adults and are best described in retrospective cohort studies from sub-Saharan Africa. Cutaneous forms involve characteristic non-
tender, purplish, indurated skin lesions, which may be seen in 47% to 83% of affected children. Children also commonly present with lymphatic involvement (30% to 64%), a particularly aggressive form of the disease, and as many as 10% to 18% of these children may not have skin lesions. Intraoral lesions may be seen in 21% to 41%, occasionally (4%) without skin lesions. Visceral dissemination occurs in 12% to 38% of children. Median age at presentation in these studies ranges from 6 years to 10 years, and KS has been diagnosed in children as young as 10 months to 2 years. Median CD4 percentage at presentation in these studies ranges from 7.4% to 16%.

Multicentric Castleman disease presents with generalized adenopathy and fever and may progress to multi-organ failure. Primary effusion lymphoma presents with symptoms related to fluid accumulation in the pleural or pericardial space or with abdominal distention.

**Diagnosis**

Laboratory diagnosis of HHV-8 infection is most commonly based on serologic assays, such as immunofluorescence, enzyme-linked immunosorbent assay, and Western blot. However, there is no gold standard for diagnosing HHV-8 infection. Serologic tests range in sensitivity from 80% to ≥90% and interassay agreement is poor. Combination assays containing both lytic and late-phase antigens may improve detection rates. Nucleic acid-based tests, such as in situ DNA hybridization and polymerase chain reaction (PCR), are important for tissue diagnosis. Although these tests have high levels of sensitivity, their specificity and reproducibility are highly variable. Only 40% to 60% of patients with proven KS will have HHV-8 DNA in their blood or saliva detectable by PCR, and in them, positivity will vary over time.

Diagnosis of KS requires biopsy and histologic examination of affected tissues.

**Prevention Recommendations**

**Preventing Exposure**

Routine testing of children and adults for HHV-8 is not recommended; therefore, the serostatus of HIV-infected patients usually is unknown. Although the efficacy of condoms in preventing HHV-8 exposure has not been established, HIV-infected patients should use male latex condoms correctly and consistently during sexual intercourse to reduce exposure to sexually transmitted pathogens.

**Preventing First Episode of Disease**

The use of ART with suppression of HIV replication has markedly decreased the incidence of KS in HIV-infected adults. Several antiviral agents (i.e., ganciclovir, foscarnet, and cidofovir) inhibit HHV-8 replication in vitro, and data suggest that their use can prevent KS in patients who are HIV/HHV-8 coinfected. However, antiviral use for prevention of KS is not currently recommended.

**Treatment Recommendations**

**Treating Disease**

Specific treatment regimens are not included in this report because the HIV-related clinical entities associated with HHV-8, such as KS and Castleman disease, are oncologic and traditionally have been treated with cytotoxic chemotherapy. However, in HIV-infected patients with KS, effective suppression of HIV replication with ART may result in improvement in KS lesions, prevent KS progression, or prevent occurrence of new KS lesions. Therefore, ART is recommended for all HIV-infected patients with evidence of active KS and other HHV-8-associated malignant lymphoproliferative disorders.

In HIV-infected adults with KS, HHV-8 cellular viremia and higher viral load have been associated with disease progression. The vast majority of infected cells are not undergoing lytic replication, and ant-herpesvirus medications have had little or no effect on established KS or HHV-8 cellular viremia. Studies are under way of methods that induce lytic replication or attack the episomal (latent) HHV-8 genome.
In contrast to KS, in Castleman disease, many of the cells support lytic replication of HHV-8, and treatment with anti-herpesvirus drugs has led to substantial clinical improvement in some studies. IV ganciclovir or oral valganciclovir may be considered for treating multicentric Castleman disease and may be a useful adjunct for treating primary effusion lymphoma. These diagnoses are exceedingly rare in children; in such cases, adult guidelines should be consulted.

**Monitoring and Adverse Events (Including IRIS)**

KS-associated immune reconstitution inflammatory syndrome (KS-IRIS) generally describes the appearance of or paradoxical clinical worsening of KS after initiation of a potent ART regimen. KS-IRIS is not predicted by low CD4 cell count. KS-IRIS is associated with higher mortality than KS not associated with IRIS. In African cohorts, where mortality from KS-IRIS is high, chemotherapy in addition to ART was associated with increased survival.

For patients with disease manifestations of HHV-8 infection who are treated with ganciclovir or valganciclovir, refer to the chapter on CMV infections for information on treatment-associated adverse events.

**Preventing Recurrence**

Effective suppression of HIV replication with ART in HIV-infected patients with KS may result in improvement in KS lesions, prevent KS progression, or prevent occurrence of new KS lesions and is recommended for all individuals with evidence of active KS and other HHV-8-associated malignant lymphoproliferative disorders.

**Primary Prevention**

I. Is there an indication for serologic testing for HHV-8 in asymptomatic HIV-infected children (compared with not testing) to guide clinical management?

Routine testing to identify HHV-8-seropositive, HIV-infected patients is not recommended (strong, very low).

Although KS is one of the most common cancers in HIV-infected individuals, a minority of coinfected individuals will develop KS. Seroprevalence of HHV-8 varies by country, but in some areas reaches ≥50% by adulthood. Sensitivity and specificity of antibody testing vary, and HHV-8 DNA shedding in saliva and presence in plasma are not consistent. Studies are conflicting on utility of quantitative DNA PCR for prediction of risk of KS in HHV-8-seropositive, HIV-infected adults. Based on lack of accurate prediction of risk of KS by antibody and HHV-8 DNA assays, routine testing is not indicated. For someone known to be HHV-8-seropositive, that factor should be considered in discussions about ART initiation.

II. Among HIV-infected children, does initiation of ART (as compared with non-initiation) reduce the risk of KS?

Effective suppression of HIV replication with ART is recommended to reduce the risk of HHV-8-associated KS (strong, low).

Multiple observational studies in adults have shown that the incidence of KS is drastically reduced in adults on ART. In one retrospective pediatric study, 0 of 1,000 children on ART developed KS, in contrast with 32 children out of 3,000 who presented with or developed KS prior to starting ART.

III. For HIV-infected patients initiating ART, are any specific ART regimens associated with lower rates of KS?

Data are insufficient and conflicting on which to base a recommendation for a particular ART regimen for prevention of KS (weak, low).

Evidence has been conflicting as to whether non-nucleoside reverse transcriptase inhibitor (NNRTI)- or
protease inhibitor (PI)-based ART has an advantage in the prevention of KS. Laboratory evidence of PI antitumor activity exists, most notably for nelfinavir, but also for ritonavir and ritonavir-boosted lopinavir. In addition, there is preliminary evidence that PI-based therapy reduces HHV-8 DNA oropharyngeal shedding.\(^5^8\) One recent, large observational study of adults noted an advantage for PI-based therapy over NNRTI-based regimens in the prevention of KS, but other studies have found no difference between regimens.\(^5^6,^5^7\) There are no corresponding data from pediatric studies. It should be noted that 5% to 10% of new cases of KS in adults occur in those on therapy, with undetectable viral loads and/or CD4 cell counts >300 cells/mm\(^3\).\(^2^8,^2^9\)

**Treatment**

**IV. Among HIV-infected children with active KS, is treatment with ART (as compared with no ART) associated with higher rates of remission and/or decreased mortality?**

Effective suppression of HIV replication with ART is recommended for all patients with evidence of active KS and/or other HHV-8-associated malignant lymphoproliferative disorders (strong, very low).

Treatment with ART is first-line therapy against KS and other HHV-8-associated malignant proliferative disorders, and is associated with increased survival among HIV-infected children with active KS.\(^2^1,^4^4,^5^8\)

**V. Among HIV-infected children with active KS, is treatment with chemotherapy in addition to ART (as compared with ART alone) associated with higher rates of remission and/or decreased mortality?**

Systemic chemotherapy, in addition to ART, is associated with higher rates of remission and decreased mortality and is recommended for disseminated or visceral KS (stage T1 disease) and for primary effusion lymphoma (strong, low). For localized KS (stage T0 disease), the benefit of systemic chemotherapy (in addition to ART) is unclear.

There is a paucity of information to guide the clinical management of HIV-infected children with KS. The available studies were retrospective, had relatively small sample sizes, and were performed in sub-Saharan Africa.\(^4^4,^4^5,^5^8\) Data from these studies were not adjusted for KS stage or for comorbidities. Additionally, AIDS Clinical Trials Group staging classification has not been validated in children. For focal or early stage KS, HIV-infected adults have been effectively treated with ART alone.\(^5^9\) Local intralesional chemotherapy or radiation therapy may be considered for focal disease. The available evidence in children suggests that systemic chemotherapy in addition to ART is associated with increased likelihood of remission and decreased mortality. It is unclear, however, if localized disease (stage T0) can be treated effectively without systemic chemotherapy. Data are insufficient on which to base a recommendation for a particular chemotherapy regimen, and various regimens have been used in different settings. Patient clinical presentation and available therapies in the practice setting should be considered, in consultation with an oncologist.

**VI. Among HIV-infected children treated with ART who develop IRIS, is chemotherapy in addition to continuation of ART (compared with no chemotherapy) associated with higher rates of remission and/or decreased mortality?**

For patients with KS-associated IRIS, chemotherapy along with continuation of ART is recommended (strong, low).

Studies of HIV-infected adults with KS-associated IRIS (primarily from African cohorts) indicate that chemotherapy in addition to ART, as opposed to ART alone, is associated with reduced mortality.\(^5^5,^6^0\)

**Secondary Prevention**

**VII. Among HIV-infected children who achieve remission from KS, what therapies are recommended to lower the risk of recurrence?**

Effective suppression of HIV replication with ART in HIV-infected patients with KS may prevent KS progression or occurrence of new lesions and is recommended for all individuals with evidence of active or treated KS and/or other HHV-8-associated malignant lymphoproliferative disorders (strong, low).
The risk of KS recurrence has decreased in the ART era. In 1 study of adults treated with pegylated liposomal doxorubicin and ART (which continued after chemotherapy), the relapse rate was 13.5% per year, and was highest in the first year.\textsuperscript{61} In 1 large Italian study, a multivariate analysis demonstrated a strong association between use of ART and increased 10-year survival rates after KS.\textsuperscript{62}

References


